Filter
135
Filtered Results: 135
Text search:
antiepileptic
medications
Featured
Recommendations
20
New Publications
29
Language
Document type
No document type
103
Guidelines
18
Studies & Reports
6
Manuals
5
Fact sheets
2
Strategic & Response Plan
1
Countries / Regions
India
10
Nepal
4
South Africa
4
Uganda
4
Ethiopia
4
Kenya
3
Africa
3
Rwanda
2
Nigeria
2
Zimbabwe
2
Philippines
2
Latin America and the Carribbean
2
Zambia
2
South Sudan
2
Eswatini/ Swaziland
2
Ghana
1
Sierra Leone
1
China
1
Syria
1
Afghanistan
1
Malawi
1
Global
1
USA
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
South–East Asia Region
1
Paraguay
1
Bangladesh
1
Bhutan
1
Botswana
1
Liberia
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
40
Clinical Guidelines
11
Women & Child Health
6
Capacity Building
3
Public Health
3
Key Resources
3
Toolboxes
Mental Health
65
Pharmacy
12
Disability
11
TB
3
COVID-19
3
NTDs
2
AMR
2
Natural Hazards
1
NCDs
1
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)?
...
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
Low- and middle-income countries (LMICs) experience a high disease burden for epilepsy, a chronic neurological condition.The authors evaluate the cost-effectiveness of community health workers (CHWs) to improve adherence to medication for epilepsy in South Africa. They found that utilizing CHWs to i...
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
This guide was developed by AACAP to give reliable information about medication
used to treat bipolar disorder in children and adolescents to parents whose children
have been diagnosed with the illness.
The internationally recognized criteria for diagnosis of neurocysticercosis include a requirement for neuroimaging techniques, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI), ideally supported by serology. These facilities are not available in all settings, especially i...
Bulletin of the World Health Organization, 2001, 79 (4)
Bridging the Gap
This is the fifteenth edition of the lecture notes. They were first published in 1987 as a summary of the material used in the biannual epilepsy teaching weekend organised under the auspices of the UK Chapter of the International League against Epilepsy.
(Lecture series consist of a total of 59 cha...
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
Brief review of selected topics
The following pages provide a focus on selected areas in relation to neurology. The specialists who contributed the reviews are listed in the Project Team and Partners
Neurology Atlas (2004)
As part of the Mental Health Gap Action Programme, WHO has developed training manuals (Training of trainers and supervisors training manual and Training of health-care providers training manual) to support implementation of the mhGAP Intervention Guide for mental, neurological and substance use (MNS...
